NuCana Trading Down 35.2
NCNA Stock | USD 1.26 0.04 3.08% |
About 61% of NuCana PLC's investor base is looking to short. The analysis of the overall investor sentiment regarding NuCana PLC suggests that many traders are alarmed. The current market sentiment, together with NuCana PLC's historical and current headlines, can help investors time the market. In addition, many technical investors use NuCana PLC stock news signals to limit their universe of possible portfolio assets.
NuCana |
NuCana plc s stock price was down 35.2 percent during mid-day trading on Monday . The company traded as low as 0.77 and last traded at 0.80. Approximately 899,844 shares were traded during mid-day trading, an increase of 474 percent from the average daily volume of 156,901 shares. The stock had previously closed at
Read at thelincolnianonline.com
NuCana PLC Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards NuCana PLC can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NuCana PLC Fundamental Analysis
We analyze NuCana PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NuCana PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NuCana PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
NuCana PLC is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
NuCana PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NuCana PLC stock to make a market-neutral strategy. Peer analysis of NuCana PLC could also be used in its relative valuation, which is a method of valuing NuCana PLC by comparing valuation metrics with similar companies.
Peers
NuCana PLC Related Equities
ALXO | Alx Oncology | 12.16 | ||||
VINC | Vincerx Pharma | 3.57 | ||||
ABOS | Acumen Pharmaceuticals | 3.52 | ||||
SLN | Silence Therapeutics | 3.28 | ||||
INZY | Inozyme Pharma | 2.95 | ||||
CTMX | CytomX Therapeutics | 2.83 | ||||
MREO | Mereo BioPharma | 0.55 | ||||
TNYA | Tenaya Therapeutics | 0.28 | ||||
DAWN | Day One | 0.65 | ||||
RANI | Rani Therapeutics | 0.99 | ||||
ZVSA | ZyVersa Therapeutics | 3.74 | ||||
CDTX | Cidara Therapeutics | 7.17 | ||||
ZURA | Zura Bio | 8.20 | ||||
CRVS | Corvus Pharmaceuticals | 9.24 | ||||
APLT | Applied Therapeutics | 13.79 |
Complementary Tools for NuCana Stock analysis
When running NuCana PLC's price analysis, check to measure NuCana PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NuCana PLC is operating at the current time. Most of NuCana PLC's value examination focuses on studying past and present price action to predict the probability of NuCana PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NuCana PLC's price. Additionally, you may evaluate how the addition of NuCana PLC to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |